<div><p><b>Background: </b>Viral hepatitis screening and link to care is a key cancer control strategy to prevent development of liver cancer, especially in underserved populations. We lack data on determinants for viral hepatitis and liver cancer screening and care particularly in geographically spread Asian American (AA) populations.</p>

<div><p><strong><b>Background:</strong> </b>Nonalcoholic steatohepatitis (NASH) is a progressive disease characterized by liver inflammation. Emerging evidence implicates T cells in the disease pathogenesis. Our unpublished data show that CD4 T cells contribute to NASH development; however, hepatic CD4 T cell phenotypes and functions in NASH have not yet been systematically examined.</p>

<div><p><strong>Background</strong>: Sarcopenia in end-stage liver disease (ESLD) has been identified as a risk factor for increased mortality. Radiological parameters; psoas muscle area index (PMAI) &amp; transverse psoas muscle thickness index (TPMTI) assess muscle quantity. While psoas muscle density index (PMDI) assesses muscle quality. Both identify muscle wasting, atrophy &amp; myosteatosis.</p>

<div><p><b>Background: </b>Immune checkpoint therapies combination with anti-VEGF is the standard-of-care in first-line of hepatocellular carcinoma (HCC). However, only 30 % of patients present a response to first line therapy. Autophagy inhibitors were recently spotted out as a potential robust strategy to promote antigen presentation and therefore reinforce immune checkpoint inhibitors (ICIs) potency conducting to strong anti-tumoral response.

<div><p><strong><b>Background:</strong> </b>Severe alcoholic hepatitis (SAH) is associated with malnutrition, dysbiosis and inflammatory cytokines augmenting liver injury resulting in high mortality. Experimental studies have reported that in comparison to unsaturated fat (UF), saturated fat (SF) improves dysbiosis, inflammation, liver enzymes and protects against alcoholic liver injury, but effect on clinical outcome and gut microbiota (GM) in SAH patients is lacking.</p>

<div><p><strong><span><b>Background:</span> </b></strong></p>

<div><p><b>Background: </b>In the Phase 2b B-Clear study (209668), bepirovirsen (BPV; an antisense oligonucleotide) 300 mg for 24 weeks (wks) achieved sustained HBsAg and HBV DNA loss (&lt;lower limit of quantification [LLOQ] for 24 wks off BPV therapy) in 9% of participants (pts) who remained on nucleos[t]ide analogs (NA); end of BPV response rates were higher (26%), but some pts relapsed during follow-up. Response was higher in pts with lower baseline HBsAg (≤3000 vs ≤1000 IU/mL: 12% vs 16%).

<div><p><b>Background:</p> </b><p>Non-alcoholic fatty liver disease (NAFLD) affects a substantial proportion of the general population, but little is known about the impact of specific nutrients on its prevention. Utilizing unbiased machine learning, we aimed to investigate the association between dietary nutrients and the development of NAFLD in the large UK Biobank dataset.</p>

<div><p><b>Background: </b>Patients with decompensated cirrhosis (DC) often experience high psychological symptom burden. Family caregivers of patients with DC are at risk for psychological distress.</p>

<div><p><strong><b>Background:</strong> </b>Acute kidney injury (AKI) is a deadly complication of cirrhosis, and treatments are limited. Vasoconstrictors have been used to treat hepatorenal syndrome AKI (HRS-AKI), but the impact of augmenting mean arterial pressure (MAP) on all AKI types has not been studied, limiting the application of clinically-proven treatments for HRS-AKI to non-HRS-AKI. Herein, we precisely characterize the impact of MAP on AKI reversal, independent of subtype.</p>